May 02, 2025

NEC Laboratories Europe and Data-Driven.AI enhance AI medical diagnosis to improve the early detection of disease and illness

NEC Laboratories Europe and Data-Driven.AI enhance AI medical diagnosis to improve the early detection of disease and illness

HEIDELBERG, Germany, April 15, 2025 – NEC Laboratories Europe and Data-Driven.AI are working together to enhance medical laboratory diagnosis and increase the effectiveness of preventive health measures and early clinical intervention to improve the well-being of patients.

If detected early, many illnesses and diseases can be managed or resolved without serious complications. However, by the time recognizable symptoms present themselves, conditions may already be advanced. In addition, doctors may miss symptoms that call for a specific range of tests to confirm a diagnosis.

Giampaolo Pileggi, Project Manager in Biomedical AI at NEC Laboratories Europe, explains, “The human body is incredibly complex, its organ systems working in harmony to keep us healthy. Over time, a minor issue with one system can quickly become serious and affect others.” He adds, “Doctors can greatly benefit from AI systems that can uncover hidden correlations in medical data, detecting even the slightest anomalies that may indicate an imbalance in the body. These advanced tools can help physicians to intervene promptly, improving diagnosis and patient care.”

In regions such as Europe, where age-related illnesses are common, prevention and early-stage intervention are critical to help maintain healthy living and control health services costs.

Standard blood tests identify low or elevated levels that may be cause for concern, thus providing clear hints to problematic anomalies, but diagnosing an underlying cause often requires further investigation.

NEC Laboratories Europe and Data-Driven.AI are using machine learning to identify unique patterns in blood results that may call for further investigation. Using embedding propagation, NEC technology combines blood analysis information with other patient information to build a condensed representation of their health, which can be used to help predict future patient conditions through additional recommended testing.

Diego Facchini, CEO and founder of Data-Driven.AI, says, “As humans, we exhibit characteristic responses to infections, illnesses or imbalances within our bodies, which can be detected through patterns in normal blood values or specific markers found in laboratory diagnostics.” He further explains, “The continuous training and refinement of AI models have the potential to revolutionize early disease detection by identifying subtle deviations in a person’s health that might be overlooked by traditional methods. By leveraging machine learning algorithms and vast datasets, AI can enhance diagnostic accuracy and improve predictive capabilities, which represent a significant breakthrough in the field of disease detection and prevention.”

NEC technology’s ability to detect subtle nuances in a patient’s well-being or current health status has a wide range of potential applications, such as predicting unexpected events in intensive care units and helping diagnose long COVID and the early onset of neurodegenerative diseases such as Parkinson’s.

About NEC Laboratories Europe
NEC Laboratories Europe research and develop cutting-edge technology to create innovative social solutions. Located in Heidelberg, Germany, major research areas of NEC Laboratories Europe include artificial intelligence, blockchain security, 5G and 6G networks, and IoT platforms. These technologies promote NEC Group solutions for a better society in the fields of digital health, safer cities, public services and communication infrastructure. 

For more information visit https://www.neclab.eu.

About Data-Driven.AI
Data-Driven.AI is a technology company specializing in artificial intelligence and software development, creating innovative solutions that transform data into actionable insights. By leveraging advanced machine learning algorithms, predictive analytics and automation, the company designs and develops AI-driven software applications that optimize business processes, enhance decision-making and unlock new opportunities across industries. With a strong focus on innovation, Data-Driven.AI empowers organizations to harness the full potential of their data, improving efficiency, accuracy and scalability in an increasingly digital world.

For more information visit https://www.data-driven.ai.

Our latest News

discover more
PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

PL BioScience Raises the Bar in Cell Culture Technology with First Artificial Human Platelet Lysate Worldwide

World Novelty: Artificial HPL Solution First Artificial Human Platelet Lysate BioScience Raises the Bar in Cell Culture Technology with artificial HPL PL BioScience develops worldwide first artificial Human Platelet Lysate (HPL) solution, and thus a key ingredient for the research & production of cell-based pharmaceuticals. In partnership with the Korean biotech DewCell Biotherapeutics, PL BioScience […]

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

EditCo Bio and Promega partner to usher in a new era of biologically relevant cell-based research

More Information in German below. EditCo Bio und Promega schließen Partnerschaft, um eine neue Ära biologisch relevanter zellbasierter Forschung einzuläuten Redwood City, CA, USA. (12. Mai 2025) EditCo Bio, Inc. hat eine strategische Lizenzvereinbarung mit der Promega Corporation bekannt gegeben, die EditCo den Zugang zu den Technologien HiBiT, HaloTag® und NanoLuc® von Promega ermöglicht. Diese fortschrittlichen […]

Affimed Announces Filing for the Opening of Insolvency Proceedings

Affimed Announces Filing for the Opening of Insolvency Proceedings

MANNHEIM, Germany, May 13, 2025 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced its decision to file an application for opening of insolvency proceedings with the local court of Mannheim in Germany. As previously reported, Affimed N.V. (the “Company”) […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp